Page results
-
Doctors at UCLH and University College London (UCL) have developed a digital decision-making aid, MENO.pause, to help clinicians manage menopause symptoms in the best way for individual patients’ health conditions.
-
One of our patients who is recovering from COVID-19 has been appearing across national media as she recounts her story and thanks the staff who saved her life.
-
UCLH is managing one of the three cancer hubs across London, so that during the COVID-19 coronavirus pandemic cancer surgery is available for patients with the most immediate needs.
-
Information on how we ask for your consent to treatment, and Martha's Rule.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
Information about making a donation to the Haematology Cancer Care charity fund at UCLH
-
This page is for cancer patients receiving immunotherapy treatment.
-
At University College London Hospitals NHS Foundation Trust (UCLH) we value our reputation for top quality care and financial probity and conduct our business in an ethical manner.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
File results
-
FOI/2024/0254 - Urothelial and endometrial cancer treatments
-
FOI/2024/0255 - Ingenica stock management system in theatres
-
FOI/2024/0259 - Clinical attachments for international medical graduates
-
FOI/2024/0263 - Longest wait for ophthalmology pathway treatment
-
FOI/2024/0268 - Module on imaging offered to PAs as training in requesting ionising radiation
-
FOI/2024/0269 - Paediatric audiology services
-
FOI/2024/0273 - Covid restrictions for visitors at Elizabeth Garret Anderson (EGA) from December 2021-June 2022
-
FOI/2024/0274 - Number of endoscopes at Trust
-
FOI/2024/0277 - Paediatric respiratory admission rates 2018-2023
-
FOI/2024/0279 - Social media management platforms and tools